MedTrace Logo

Covid-19 Vaccine Response in Elderly Subjects

NCT04760704 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2025-12-26

No results posted yet for this study

Summary

The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9 months, in subjects residing in medical establishment for dependent elderly persons, compared to immunocompetent subjects aged 40 to 65 years (control subjects for vaccination over the same period).

Conditions

  • Covid19 Vaccine

Interventions

BIOLOGICAL

Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration

Specific T cells and specific antibodies assessment

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Guillaume LEFEVRE, MD,PhD · University Hospital, Lille

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2023-03-28
Completion
2023-03-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04760704 on ClinicalTrials.gov